Human Genome Epidemiology Literature Finder
Records 1 - 3 (of 3 Records) |
Query Trace: Hypertension and PDGFRA[original query] |
---|
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study. BMC cancer 2012 12 (1): 107. Rutkowski Piotr, Bylina El?bieta, Klimczak Anna, Switaj Tomasz, Falkowski S?awomir, Kroc Jacek, Lugowska Iwona, Brzeskwiniewicz Magdalena, Melerowicz Wojciech, Osuch Czes?aw, Mierzejewska Ewa, Wasielewski Kacper, Wo?niak Agnieszka, Grzesiakowska Urszula, Nowecki Zbigniew I, Siedlecki Janusz A, Limon Janu |
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2016 Jul . Ben-Ami E, Barysauskas C M, von Mehren M, Heinrich M C, Corless C L, Butrynski J E, Morgan J A, Wagner A J, Choy E, Yap J T, Van den Abbeele A D, Solomon S M, Fletcher J A, Demetri G D, George |
A phase II study of a human anti-PDGFRa monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors. Annals of oncology : official journal of the European Society for Medical Oncology 2017 Mar 28 (3): 541-546. Wagner A J, Kindler H, Gelderblom H, Schöffski P, Bauer S, Hohenberger P, Kopp H-G, Lopez-Martin J A, Peeters M, Reichardt P, Qin A, Nippgen J, Ilaria R L, Rutkowski |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 16, 2024
- Content source: